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Abstract: The steroidogenic 18 kDa translocator protein (TSPO) is an emerging, attractive
therapeutic tool for several pathological conditions of the nervous system. Here, 13 high affinity
TSPO ligands belonging to our previously described N,N-dialkyl-2-phenylindol-3-ylglyoxylamide
(PIGA) class were evaluated for their potential ability to affect the cellular Oxidative Metabolism
Activity/Proliferation index, which is used as a measure of astrocyte well-being. The most active
PIGA ligands were also assessed for steroidogenic activity in terms of pregnenolone production,
and the values were related to the metabolic index in rat and human models. The results showed
a positive correlation between the increase in the Oxidative Metabolism Activity/Proliferation
index and the pharmacologically induced stimulation of steroidogenesis. The specific involvement
of steroid molecules in mediating the metabolic effects of the PIGA ligands was demonstrated
using aminoglutethimide, a specific inhibitor of the first step of steroid biosynthesis. The most
promising steroidogenic PIGA ligands were the 2-naphthyl derivatives that showed a long residence
time to the target, in agreement with our previous data. In conclusion, TSPO ligand-induced
neurosteroidogenesis was involved in astrocyte well-being.
Keywords: translocator protein; neurosteroidogenesis; PIGA ligands; cellular proliferation; oxidative
metabolism; astrocytes
1. Introduction
Neuroactive steroids, which are mainly synthesized by glial cells, exert peculiar actions to
influence the development and function of the nervous system through both genomic and non-genomic
mechanisms [1,2]. The classic genomic action involves steroid binding to intracellular receptors and the
regulation of protein translation [3]. Neuroactive steroids can also show rapid effects, occurring within
seconds to minutes, via the activation of membrane neurotransmitter receptors. It has been shown
that neuroactive steroids determine the allosteric modulations on ligand-gated channels, including
type-A γ-aminobutyric acid (GABA), N-methyl-D-aspartate (NMDA), and nicotinic receptors [1,4–11].
These different interactions lead to the multiple actions of neuroactive steroids, affecting both
glia and neurons in a concerted manner [12]. For instance, oestrogens act as transcriptional
regulators to modulate the synthesis of various proteins and growth factors in astrocytes [13–25].
Interestingly, oestrogens increase glutamate transporter expression in astrocytes via the nuclear factor
κ-light-chain-enhancer of activated B cells (NF-κB) and the cAMP response element binding protein
(CREB) pathways [26]. Among the actions exerted by steroids, the increase in the expression of the
mitochondria-encoded subunits of the respiratory chain influences the mitochondrial respiratory
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function, and this activity may be of particular interest for enhancing the functional efficiency of
astrocytes [27,28].
Notably, bidirectional glia-neuron communication was suggested by several scientific reports
showing that glial cells and neurons can respond to the same signals and that they can mutually
modulate the cellular response (for a review see [12]). For this reason, glial cell well-being is of
particular importance for the efficiency of the whole brain.
Translocator protein 18 kDa (TSPO), which is primarily located in the outer mitochondrial
membrane, is highly expressed in steroid-synthesizing tissues, including glial cells. Although few
reports questioned the role of TSPO in steroidogenesis [29–31], most studies, including the most
recent ones, propose that TSPO is an important protein for steroid synthesis [32–34]. TSPO binds
cholesterol with high affinity and, in a combined action with the steroidogenic acute regulatory protein
(StAR), allows cholesterol to translocate into mitochondria, which represents the rate-limiting step of
steroidogenesis [35–37]. The steroid biosynthetic pathway is triggered by the cleavage of the cholesterol
aliphatic side chain, which is catalyzed by the cytochrome P450 side chain cleavage (P450scc) enzyme,
producing pregnenolone. Then, pregnenolone is converted to other neurosteroids by enzymes located
in the endoplasmic reticulum, such as hydroxysteroid dehydrogenases [38,39].
A number of TSPO-targeted molecules have been reported as neuroprotective, anti-inflammatory,
and regenerating agents in different in vitro and in vivo models, suggesting their possible development
as effective therapeutic tools (for a review see [40]). For instance, in gliosis, TSPO ligands were able to
decrease reactive gliosis and prevent neuronal loss [41,42]. The stimulation of neurosteroidogenesis
has been hypothesized as the basis for the positive actions of the TSPO ligand [43], and, for these
reasons, TSPO ligands are currently under investigation as therapeutic tools to preserve a functional
brain environment and the glia-neuron bidirectional interactions [44]. Very recently, we have found
that the N,N-dialkyl-2-phenylindol-3-ylglyoxylamide class (PIGAs) of TSPO ligands reduces oxidative
stress and the activity of pro-inflammatory enzymes in rat glial cells through the de novo neurosteroid
synthesis [45].
Based on the previously described pro-survival activity of TSPO ligands in neurons and glia, in
the present work, the effects of the TSPO ligands on astrocyte well-being were assessed by focusing on
the involvement of steroidogenesis. Therefore, the residence time of some investigated ligands were
also assessed because we have recently shown that the time over which a ligand interacts with TSPO
directly affects its steroidogenic efficacy [46]. The human glioblastoma–astrocytoma cell line U87MG
and normal human astrocytes were used as cellular models. U87MG cells express the astrocyte cell
marker glial fibrillary acidic protein (GFAP) and are widely used as an in vitro astrocyte model [47–50].
Recent data have shown comparable responses of U87MG cells and primary human astrocytes after
inflammatory insult, highlighting the potential use of U87MG cells in drug discovery stages, as it is
not feasible to screen compounds in primary human cells [50]. However, data from healthy human
astrocytes were crucial for validating TSPO activity under normal conditions. Thus, 13 high affinity,
selective TSPO ligands belonging to our previously described PIGA class [51,52] were selected and
evaluated for their ability to increase the Oxidative Metabolism Activity/Proliferation index in human
astrocyte models. The most promising compounds were then assessed for their steroidogenic activity
and residence time. Finally, the relation between oxidative metabolism, proliferation activity, and the
induction of neurosteroidogenesis was investigated.
2. Results
2.1. N,N-Dialkyl-2-phenylindol-3-ylglyoxylamide (PIGA) Ligands Increase the Oxidative Metabolism
Activity/Proliferation Index in a Human Astrocyte Model
TSPO expression has previously been established in U87MG cells [53]. To assess the potential
effects of the PIGA ligands on the activation of oxidative metabolism, U87MG cells were cultured under
serum-reduced growth conditions; serum starvation is a well-known method to arrest the cells in a basal
metabolic state (G0/G1 phase) [54,55]. The metabolic activity of the astrocyte models was estimated
Int. J. Mol. Sci. 2016, 17, 1028 3 of 16
using the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt) (MTS) assay [56]. This tetrazolium dye can be reduced by the metabolic reducing agents
NADH and NADPH to a water-soluble formazan salt; the amount of produced formazan has been
considered a marker of the Oxidative Metabolic Activity index [57]. The redox reactions can occur
in both the mitochondria and cytosol; in particular, it has been shown that tetrazolium reduction
mainly reflects cytosolic redox activity in astroglia and is dependent on glyceraldehyde-3-phosphate
dehydrogenase activity [56]. Furthermore, as the reduction of the tetrazolium compound can only be
achieved in viable cells, the tetrazolium assay has also been widely used for the quantitative assessment
of cellular proliferation for over three decades [56,57].
The effects of PIGAs and the TSPO reference standard ligand PK11195 (ranging from nanomolar
to micromolar concentrations) on the Oxidative Metabolism Activity/Proliferation (OMAP) index in
U87MG cells were evaluated after 48 h of incubation. The derivatives PIGA1128, PIGA1130, PIGA1136,
PIGA1137, PIGA1138, PIGA1165, PIGA1174, PIGA1175, and PIGA1212 significantly increased the
OMAP index, with the maximal mean value (163%) observed for 1 µM PIGA1138 (p < 0.001 vs. the
control) (Figure 1).
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Figure 1. Effects of the PI ligan s on the Oxidative Metabolism Activity/Proliferation index
in U87MG human glioma cells. U87MG cells were treated with different concentrations of the
compounds (10 n –1 µM) in serum-reduced media (1% fetal bovine serum (FBS)), and the
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt] (MTS) assay was performed after 48 h of treatment. The data are expressed as percentages of the
proliferative/oxidative etabolis activity index co pared to the control (0.1 di ethyl sulfoxide
(DMSO), a concentration that not interfered with the assay), which was set to 100%, and represent
the means ˘ standard error of the mean (SEM) of three different experiments performed in duplicate.
The statistical analysis was performed using one-way analysis of variance (ANOVA) and Bonferroni’s
post-test; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control.
The most promising derivatives were those featuring a 2-naphthyl substituent as an aryl group
(PIGA1128, PIGA1136, PIGA1137, and PIGA1338; see Table 1 for the chemical structures). In particular,
PIGA1136 and PIGA1138 yielded statistically significant results at all tested concentrations. PIGA1174
and PIGA1175 were significantly effective at 10 and 100 nM, the two lowest concentrations tested.
Conversely, PIGA1128, PIGA1130, PIGA1137, and PIGA1165 were active at the higher doses of 100 nM
and 1 µM. Statistically significant results were not observed for PIGA1226, PIGA1228, PIGA1244,
Int. J. Mol. Sci. 2016, 17, 1028 4 of 16
PIGA1248, and the reference compound PK11195. These results suggested that the TSPO ligands
positively affected the well-being of an astrocytic cell line when the cells were maintained in a
constrained low metabolic state.
Table 1. TSPO binding affinity of the compounds. The concentration of the tested compounds
that inhibited [3H]PK11195 binding to rat kidney mitochondrial membranes (IC50) by 50% was
determined using six concentrations of the displacers, each performed in triplicate. The Ki values are
the means ˘ SEM of three determinations.
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2.2. PIGA Ligands Effectively Stimulate Steroidogenesis in Vitro
To assess the ability of PIGA ligands to stimulate steroidoge esis in vitro, the synthesis of the
first steroid metabolite preg nolon was evaluated in the presence of inhibitors of preg nolone
metabolism. As a first step, the assessment was performed in a rat C6 cell line, the glial cell el that is
conventionally used to measure mitochondrial receptor-regulated steroid genesis [58]. The amount of
pregnenolo e released from the C6 cells was measured after a 2 h incubation with a fixed concentration
of the most promising PIGAs in terms of etabolic activation (PIGA1128, PIGA1130, PIGA1136,
PIGA1137, and PIGA1138).
The obtained results showed that all PIGA derivatives significantly increased preg enolone
synthesis in the C6 cells compared to the control (cells treate with DMSO and set to 100%) (Figure 2A
and Table 2). The ighest pregne ol ne level was observed after t e 6 cells were treated with
PIGA1137 and PIGA1138 (i crease i reg enolone synthesis of 208% and 215%, respectively, p < 0.001)
(Figure 2A and Table 2).
To explore whether the promising steroidogenic effects of the PIGA ligands were maintained in a
human astrocytic model, the pregnenolone assessment was performed in U87MG cells. As shown in
Figure 2B and Table 2, the PIGA ligands also significantly induced steroidogenesis in the U87MG cells,
and the results were comparable to those obtained in the C6 cells. The best performing derivatives
were PIGA1137 and PIGA1138, showing an increase in pregnenolone synthesis of 288% and 299%,
respectively (p < 0.001; Figure 2B and Table 2). Notably, these two PIGA ligands also presented
the best metabolic activation profile in the U87MG cells. The standard PK11195 similarly increased
pregnenolone production in the C6 and U87MG cells (139% and 144%, respectively, p < 0.01) (Figure 2).
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Figure 2. Effects of the PIGA ligands on pregnenolone production. C6 glio a cells (A) and U87 G
cells (B) were incubated with different PIGA ligands (40 µM) for 2 h at 37 ˝C. The pregnenolone amounts
were quantified by a competitive enzyme-linked i munosorbent assay. The data are expressed as
percentage of pregnenolone production compared to the control, which was set to 100%, and represent
the means ˘ SEM of three different determinations performed in duplicate. The statistical analysis was
performed using ne-way ANOVA and Bonferroni’s post-test; * p < 0.05, ** p < 0.01, *** p < 0.001 vs.
the control.
Table 2. Pregnenolone production in C6 and U87MG cells. The data are expressed as percentage
of pregnenolone production compared to the control, which was set to 100%, and represent the
means ˘ SEM of three different determinations performed in duplicate. The statistical analysis was
performed using one-way ANOVA and Bonferroni’s post-test.
Compounds Pregnenolone Productionin C6 cells (% ˘ SEM) p
Pregnenolone Production
in U87MG cells (% ˘ SEM) p
PIGA1128 148.4 ˘ 4.643 <0.01 190.0 ˘ 8.356 <0.001
PIGA1136 164.0 ˘ 2.096 <0.01 177.3 ˘ 7.963 <0.001
PIGA1130 155.0 ˘ 5.774 <0.01 145.8 ˘ 3.393 <0.01
PIGA1137 208.0 ˘ 4.933 <0.001 287.6 ˘ 11.98 <0.001
PIGA1138 245.0 ˘ 5.774 <0.001 298.7 ˘ 10.14 <0.001
PK 11195 138.5 ˘ 9.717 <0.05 143.8 ˘ 20.40 <0.01
2.3. The Best Performing PIGA Ligands in Terms of Steroidogenesis Stimulation Are Characterized by a Long
Residence Time
Our very recent results have shown that the time over which a ligand interacts with TSPO
directly affects its steroidogenic efficacy [46]. The time of the ligand-target interaction is a kinetic
parameter known as Residence Time (RT), and it is calculated by the reciprocal of the dissociation
rate constant (koff). For unlabelled TSPO ligands, koff is experimentally derived by the competition
kinetic association assay [46]. The RT values of the most promising compounds were evaluated
to relate the TSPO kinetic binding parameters and steroidogenic activity of the PIGA ligands.
Consistent with our previous results, the 2-naphthyl derivative PIGA1138, which is characterized
by a long RT (141 min) [46], was the best performing ligand in terms of its ability to stimulate
steroidogenesis in both the C6 and U87MG cells. In contrast, the standard PK11195, which is
characterized by a short RT (33 min) [46], showed a reduced ability to stimulate steroidogenesis
compared to PIGA1138. The RT of PIGA1128 has been already determined (55 min) [46]; as expected,
it showed an intermediate ability to stimulate steroidogenesis. The RTs of additional 2-naphthyl
derivatives with promising steroidogenic ability in human U87MG cells (PIGA1136 and PIGA1137)
were here examined. Kinetic experiments showed that the association rate constant (kon), koff and RT
value for PIGA1136 were 2.52ˆ 107 M´1¨min´1, 0.0178 min´1 and 56 min, respectively. For PIGA1137,
the kon, koff and RT values were 3.56 ˆ 107 M´1¨min´1, 0.0185 min´1 and 54 min, respectively.
For PIGA1136 and PIGA1137, the kinetically derived Kd values (koff/kon) were 0.71 and 0.52 nM,
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respectively. These values were in good agreement with the previously reported Ki values [52]
obtained from competition binding experiments at equilibrium (the Ki values for PIGA1136 and
PIGA1137 were 0.53 and 0.56 nM, respectively).
2.4. The Oxidative Metabolism Activity/Proliferation Index of PIGA1138 Is Related to Steroid Production
The OMAP index and the percentage of pregnenolone production could not be directly compared,
as they were obtained in different experimental settings. However, the correlation analyses indicated
a strong relationship between these two parameters. Indeed, Spearman’s correlation analysis of the
OMAP index and pregnenolone production in U87MG cells treated with micromolar concentrations of
the compounds revealed a highly significant p value (p = 0.0004, Figure 3).
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Figure 3. Spearman’s correlation analyses of the Oxidative Metabolism Activity/Proliferation (OMAP)
index and pregnenolo e production in U87MG cells. The percentages of pregnenolone production
obtai ed in th steroidogenesis experiments (U87MG cells were expo ed to 40 µM PIGA ligand in
saline mediu for 2 h) were correlated to the OMAP indexes obtained in the metabolic experi ents
(U87MG cells were exposed to 1 µM PIGA ligand in serum-reduced medium for 48 h). The statistical
analyses were performed using the Spearman r correlation, reporting a p < 0.001.
To deeply investigate the correlation between the ability of the most promising PIGA ligands
to promote astrocyte survival and their neurosteroidogenic activity, the ligand-mediated metabolic
activation of U87MG cells was evaluated in the presence and absence of DL-aminoglutethimide
(AMG), an inhibitor of cytochrome P450 side chain cleavage (P450scc), the enzyme that catalyzes
the first step of steroidogenesis. The assay was performed for PIGA1138, which was selected as the
most representative compound based on its ability to effectively increase both the OMAP index and
pregnenolone production. The cells were maintained in a serum-reduced growth condition; in this
basal metabolic state, AMG alone did not affect the OMAP index (Figure 4).
The results showed that PIGA1138 increased the OMAP index of the U87MG cells in a
concentration-dependent manner and the effects were completely counteracted by the co-treatment
with AMG (Figure 4), clearly supporting the hypothesis that the PIGA ligand-induced increase in the
OMAP index was mainly related to steroid production.
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Figure 4. Influence of pregnenolone production on the U87MG OMAP index. U87MG cells were treated
with different concentrations of PIGA ligands (1 nM–10 µM) in the absence or presence of AMG (50 µM)
in serum-reduced media (1% FBS), and the viable cells were counted after 48 h of treatment using
the MTS assay. The data are expressed as percentages of the OMAP index compared to the control,
which was set to 100%, and represent the means ˘ SEM of three different experiments performed in
duplicate. The statistical analysis was performed using one-way ANOVA and Bonferroni’s post-test;
** p < 0.01, *** p < 0.001 vs. the control; ## p < 0.01, ### p < 0.001 vs. the respective treatment without
DL-a inoglutethimide (AMG).
2.5. PIGA1138 Promoted the Activation of Oxidative Metabolism in Normal Human Astrocytes
Although the U87MG cell line is widely used as an astrocyte model in vitro, we verified the
consistency of the obtained data by evaluating the effects of PIGA1138 and PK11195 on healthy normal
human astrocytes. As first step, the TSPO expression levels were quantified using [3H]PK11195 as a
probe. In the whole membranes derived from normal human astrocytes, the [3H]PK11195 binding
reached saturation, showing a maximal binding capacity of 9.548 fmol/mg. In terms of the equilibrium
dissociation constant, the experimentally derived [3H]PK11195 binding affinity was 2.8 nM.
Then, the effects of PIGA1138 and PK11195 on healthy normal human astrocytes maintained
under serum-reduced growth conditions were evaluated (Figure 5A). PK11195 did not increase the
astrocytes’ OMAP index. In contrast, PIGA1138 significantly promoted the astrocytes’ well-being
(p < 0.001) (Figure 5A), in accordance with the data obtained in the U87MG cells (Figure 1).
Finally, to verify if the serum-reduced conditions used in the experiments could affect the
obtained results, parallel cell cultures maintained under normal growth conditions (20% serum
medium) were treated with ligand and assessed. As shown in Figure 5B, PIGA1138 also increased
the astrocytes’ OMAP index under the normal growth culture conditions, whereas PK11195 did not
affect the astrocytes’ well-being. The results obtained for PIGA1138 are in accordance with those
obtained in astrocytes grown under serum-reduced conditions, suggesting that the increase in steroid
production exerted a positive effect when the cells were maintained in a housekeeping metabolic state
and promoted the general well-being of the astrocytes under normal growth conditions.
Int. J. Mol. Sci. 2016, 17, 1028 8 of 16
Int. J. Mol. Sci. 2016, 17, 1028 7 of 15 
 
2.5. PIGA1138 Promoted the Activation of Oxidative Metabolism in Normal Human Astrocytes 
Although the U87MG cell line is widely used as an astrocyte model in vitro, we verified the 
consistency of the obtained data by evaluating the effects of PIGA1138 and PK11195 on healthy 
normal human astrocytes. As first step, the TSPO expression levels were quantified using 
[3H]PK11195 as a probe. In the whole membranes derived from normal human astrocytes, the 
[3H]PK11195 binding reached saturation, showing a maximal binding capacity of 9.548 fmol/mg. In 
terms of the equilibrium dissociation constant, the experimentally derived [3H]PK11195 binding 
affinity was 2.8 nM. 
Then, the effects of PIGA1138 and PK11195 on healthy normal human astrocytes maintained 
under serum-reduced growth conditions were evaluated (Figure 5A). PK11195 did not increase the 
astrocytes’ OMAP index. In contrast, PIGA1138 significantly promoted the astrocytes’ well-being  
(p < 0.001) (Figure 5A), in accordance with the data obtained in the U87MG cells (Figure 1). 
Finally, to verify if the serum-reduced conditions used in the experiments could affect the 
obtained results, parallel cell cultures maintained under normal growth conditions (20% serum 
medium) were treated with ligand and assessed. As shown in Figure 5B, PIGA1138 also increased 
the astrocytes’ OMAP index under the normal growth culture conditions, whereas PK11195 did not 
affect the astrocytes’ well-being. The results obtained for PIGA1138 are in accordance with those 
obtained in astrocytes grown under serum-reduced conditions, suggesting that the increase in steroid 
production exerted a positive effect when the cells were maintained in a housekeeping metabolic 
state and promoted the general well-being of the astrocytes under normal growth conditions. 
(A) (B)
Figure 5. In vitro response of the human astrocytes to the PIGA1138 and PK11195 treatments.  
(A) Human astrocytes were treated with different concentrations of PIGA1138 and PK11195  
(10 nM–1 µM) in serum-reduced media (1% FBS), and the MTS assay was performed after 48 h of 
treatment; (B) Human astrocytes were treated with different concentrations of PIGA1138 and 
PK11195 (10 nM–1·µM) in complete medium and the MTS assay was performed after 48 h of 
treatment. The data are expressed as percentages of metabolic activity compared to the control, which 
was set to 100%, and represent the means ± SEM of three different experiments performed in 
duplicate. ** p < 0.01, *** p < 0.001 vs. the control. 
3. Discussion 
In this study, TSPO PIGA ligand treatments showed a positive relation between steroidogenesis 
induction and the Oxidative Metabolism Activity/Proliferation Index in rat and human cell models. 
Notably, the data obtained in these astrocytic cell models were consistent with those acquired in 
healthy human astrocytes. Firstly, the ability of a number of PIGA ligands to stimulate the OMAP 
index was shown. Then, the ability of the ligands to induce steroidogenesis was evaluated and related 
Figure 5. In vitro response of the human astrocytes to the PIGA1138 and PK11195 treatments.
(A) Human astrocytes were treated with different concentrations of PIGA1138 and PK11195
(10 nM–1 µM) in serum-reduced media (1% FBS), and the MTS assay was performed after 48 h of
treatment; (B) Human astrocytes were treated with different concentrations of PIGA1138 and PK11195
(10 nM–1¨µM) in complete medium and the MTS assay was performed after 48 h of treatment. The data
are expressed as percentages of metabolic activity compared to the control, which was set to 100%,
and represent the means ˘ SEM of three different experiments performed in duplicate. ** p < 0.01,
*** p < 0.001 vs. the control.
3. Discussion
In this study, TSPO PIGA ligand treatments showed a positive relation between steroidogenesis
induction and the Oxidative Metabolism Activity/Proliferation Index in rat and human cell models.
Notably, the data obtained in these astrocytic cell models were consistent with those acquired in healthy
human astrocytes. Firstly, the ability of a number of PIGA ligands to stimulate the OMAP index was
shown. Then, the ability of the ligands to induce steroidogenesis was evaluated and related with their
TSPO residence time. It is likely that the metabolic stimulation was mediated by the modulation of
steroid levels, as the positive effects of the compounds were completely counteracted by the treatment
with the neurosteroid synthesis inhibitor AMG.
As previously reported in the nervous system, neuroactive steroids exert several direct regulatory
activities on neurons and glial cells [59–66]; the role of TSPO in the release of neurosteroids led us to
investigate the relation among the TSPO compound binding ability, OMAP index, and neurosteroid
release in rat and human astrocytes. We selected a number of previously reported PIGA ligands
with high affinities towards TSPO. The PIGA-induced increase in the OMAP index showed a good
agreement with previous data reporting that three different TSPO ligands (triakontatetraneuropeptide,
octadecaneuropeptide and Ro5-4864), at low concentrations, induce a dose-dependent increase in DNA
synthesis in rat primary astrocytes by activating TSPO [67,68]. These results provide the evidence of
a role for TSPO ligands in the control of glial cell proliferation. Indeed, although some forerunner
studies have shown that low ligand concentrations inhibit astrocyte proliferation [69,70], most studies
have shown a proliferative role for TSPO ligands. For instance, TSPO-related proliferation has been
evaluated in C6 glioma cells in serum-free medium, as well as in a standard fibroblast cell line, showing
that nanomolar concentrations of PK11195 and Ro5-4864 increased the growth rate and [3H]thymidine
incorporation [71]. A significant increase in [3H]thymidine incorporation in human glioma cells
following treatment with 10 nM PK11195 in serum-free media has been confirmed; the same study
also showed an increase in mitochondrial mass and lipid fluidity [72]. It has been suggested that the
Int. J. Mol. Sci. 2016, 17, 1028 9 of 16
changes in mitochondrial lipid metabolism might lead to mitochondrial biogenesis to support the
increased metabolic requirements for cell division [72–74].
Concerning the well-known discrepancy between the functional efficacy and affinity of TSPO
ligands [75], the PIGA compounds used here presented different functional effects on astrocytes in
terms of the OMAP index, despite their similar TSPO affinities. Interestingly, the PIGA compounds
that were able to interact with TSPO for a longer time (high RT) also presented higher pregnenolone
synthesis induction and promoted better astrocyte well-being, in accordance with our previous data
suggesting that the residence time is a predictive parameter for estimating steroidogenic activity [46].
Consistent with the present findings, it has been shown that primary astrocytes and C6 cells that
were treated with nanomolar concentrations of PK11195 and Ro5-4864 exhibited an increase in the
progesterone content in the medium that was 2–3-fold higher than the basal levels [76]. Similarly,
the TSPO ligand AC-5216 increased the allopregnanolone level in meningioma cells [77], supporting
the theory that TSPO ligands have a role in the regulation of steroid production. To our knowledge,
this is the first study investigating steroidogenesis in a rat cellular model and in human glial cells in
parallel, showing a good agreement between the data obtained in these two different cellular models.
Steroidogenesis stimulation is a widely proposed mechanism for the neuroprotective actions of
TSPO ligands (for a review see [40]). In this line, we have recently demonstrated the involvement of
steroidogenesis in the pro-survival properties of the PIGA ligands against cytotoxic insults, such as
lipid peroxidation (induced by cellular glutathione depletion) and inflammatory responses (induced
by LPS/IFN-γ cell exposure) [45]. Moreover, the PIGA-elicited modulation of the StAR protein levels
has been recently demonstrated; in particular, we have shown that the stimulation of astroglial-derived
cells with PIGAs leads to an increase of the 30 kDa intra-mitochondrial StAR, an indirect evidence of
an increased cholesterol transfer into mitochondria [45].
It is well known that the effects of steroids are mediated by changes in cellular metabolism [78].
Here, we clearly showed that the positive effects of the PIGA ligands on the astrocytes were mediated
by steroids, as they were completely prevented by the pre-treatment with the inhibitor of steroid
synthesis, AMG. These data support the theory that the autocrine effects are due to neurosteroid
release by the astrocytes themselves.
In conclusion, the importance of the induction of neurosteroidogenesis on astrocyte well-being
was investigated in a human astrocyte model in vitro. Astrocytes play a pivotal role in the complex
central nervous system network. The loss or the gain of astrocyte functions could be the basis of several
pathological conditions [79–86]. In this respect, the positive effects of TSPO-stimulated neurosteroid
release on astrocytes well-being were demonstrated. The development of molecules able to stimulate
steroid release could represent a therapeutic strategy for central nervous system diseases characterized
by astrocyte loss. Furthermore, these ligands may be exploited as pharmacological tools to deeply
investigate the autocrine/paracrine roles of neurosteroids in the control of astrocyte metabolism.
4. Experimental Section
4.1. Materials
[3H] PK11195 (Specific Activity, 85.7 µCi/nmol) was obtained from Perkin-Elmer Life Sciences
(Perkin Elmer Italia, Monza, Italy). PK11195 and the protease inhibitors were purchased from
Sigma-Aldrich (Sigma-Aldrich S.r.l., Milan, Italy). Dulbecco’s Modified Eagle’s Medium, fetal
bovine serum, L-glutamine, penicillin, and streptomycin were purchased from Lonza (Milan, Italy).
The enzyme-linked immunosorbent assay (ELISA) used to measure the pregnenolone levels was
obtained from IBL (Hamburg, Germany). SU10603 and trilostane were gifts from Novartis Farma
(Varese, Italy) and Susanne Zister (University of Dublin, Dublin, Ireland), respectively. All other
chemical reagents were obtained from commercial sources.
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4.2. Drugs
The compounds PIGA1228, PIGA1248, PIGA1175, PIGA1165, PIGA1174, PIGA1128, PIGA1136,
PIGA1130, PIGA1137, PIGA1138, PIGA1226, PIGA1244, and PIGA1212 were synthesized according to
the experimental procedure that we previously described [51,52]. Briefly, the appropriate 2-arylindoles,
which were commercially available or easily obtained with a one-step Fischer indole synthesis,
were reacted with oxalyl chloride at room temperature in anhydrous diethyl ether to produce
the corresponding 2-arylindolylglyoxylyl chlorides. These compounds were then treated with the
appropriate dialkylamine in dry toluene solution in the presence of triethylamine at room temperature
to yield the target PIGA ligands [51,52].
4.3. Cell Culture
U87MG cells were purchased from the National Institute for Cancer Research of Genoa (Genoa
Italy) and cultured in RPMI supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine,
1% non-essential amino acids, penicillin (100 U/mL) and streptomycin (100 mg/mL) at 37 ˝C in 5% CO2.
C6 rat glioma cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with
10% FBS, 2 mM L-glutamine, penicillin (100 U/mL) and streptomycin (100 mg/mL) at 37 ˝C in 5% CO2.
Human astrocytes were obtained from GIBCO (Life Technologies, Milan, Italy). Human astrocytes were
cultured in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1% N-2 Supplement,
penicillin (100 U/mL) and streptomycin (100 mg/mL) at 37 ˝C in 5% CO2.
4.4. The Oxidative Metabolism Activity/Proliferation Index in the Astrocyte Cell Models
Rat C6 cells, human U87MG cells or human primary astrocytes were seeded in 96-well plates
(10,000 cells/well) and maintained in their specific, complete culture media for 24 h. Then, the culture
media were refreshed with serum-reduced media (1% FBS). After 16 h, the cells were treated with
increasing concentrations of the PIGA ligands (ranging from 10 nM to 1 µM) for 48 h. In the experiments
used to evaluate the specific contribution of PIGA ligand-induced steroid production, the U87MG cells
were pretreated (1 h before the addition of the PIGA ligands) with AMG (50 µM), a potent inhibitor
of steroidogenesis. After 48 h, the MTS reagent was added to the PIGA ligand-treated cells, and the
colorimetric MTS conversion was quantified after 2 h by measuring the absorbance at 490 nm with a
microplate reader (WallacVictor 2, 1420 Multilabel Counter, Perkin Elmer, MA, USA).
4.5. Pregnenolone Quantification
The amount of pregnenolone in the rat C6 and human U87MG astrocyte models were quantified
as previously reported [46]. Briefly, C6 or U87MG cells were incubated with 40 µM TSPO PIGA
ligands in saline medium (140 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgSO4, 10 mM glucose,
10 mM N-2-hydroxyethylpiperazine-N1-2-ethanesulfonic acid (HEPES)–NaOH, pH 7.4, and 0.1%
bovine serum albumin) containing the inhibitors of pregnenolone metabolism trilostane (25 µM) and
SU10603 (10 µM). After 2 h of incubation, the conditioned salt medium was collected and the amount
of pregnenolone secreted into the medium was quantified by an ELISA.
4.6. RT Determination of the TSPO PIGA Ligands
The RT values of the TSPO PIGA ligands were calculated from the reciprocal of their dissociation
rate constant (koff). The koff values were assessed by the competition kinetic association assay, as
previously reported [46]. In particular, the TSPO-specific and TSPO-selective radioligand [3H]PK11195
(approximately 20 nM, specific activity of 21.4 µCi/nmol) and PIGA ligand were simultaneously
added to the final reaction volume (500 µL) containing a rat kidney membrane homogenate (30 µg of
proteins) and assay buffer (50 mM Tris-HCl, pH 7.4). The incubation of the samples was terminated at
various times by vacuum filtration. The PIGA ligands were solubilized with DMSO and tested at a
concentration corresponding to a three-fold higher value than the respective value of the inhibition
Int. J. Mol. Sci. 2016, 17, 1028 11 of 16
constant (Ki). The Ki values have been reported previously [52]. The nonspecific binding was
determined in the presence of 1 µM PK11195. The experimentally derived data were analyzed using
the “kinetics of competitive binding” using Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA).
4.7. Radiolabel Binding Experiment in Human Astrocytes Using [3H] PK11195
For crude membranes, confluent human astrocytes derived from a 175 cm2 cell flask were
harvested using phosphate-buffered saline (PBS), pH 7.4, supplemented with EDTA 0.04%. After the
cells were collected by centrifugation (200ˆ g for 5 min), the pellet was suspended in 10 mL of
ice-cold buffer (5 mM Tris–HCl, pH 7.4 containing protease inhibitors (160 µg/mL benzamidine,
200 µg/mL bacitracin and 20 µg/mL trypsin inhibitor)) and homogenized with an Ultraturrax.
Then, the homogenate was centrifuged at 48,000ˆ g for 15 min at 4 ˝C and the supernatant was
discarded. The obtained pellet was suspended in 10 mL of 50 mM Tris–HCl, pH 7.4 (assay buffer)
containing the same amounts of protease inhibitors as described above, and the homogenate was
pelleted by centrifugation (48,000ˆ g for 15 min at 4 ˝C). The pellet was washed once with assay buffer
and an additional centrifugation step was performed (48,000ˆ g for 15 min at 4 ˝C). The resulting
cell membrane pellet was suspended at a final concentration of 1 mg of protein/mL in assay buffer
and used for the binding assays. The protein content of a 20 µL membrane suspension was measured
by the Bradford method using the Bio-Rad Protein Assay reagent, according to the manufacturer’s
protocol, with bovine serum albumin (BSA) as the standard.
To determine the specific binding of [3H]-PK11195 to the human astrocyte membrane suspensions,
equilibrium radioligand binding assays were performed essentially as previously described [46,87].
Briefly, different aliquots of human astrocyte membranes (10–100 µg of proteins) were incubated with
[3H]-PK11195 (1.5 nM) in the presence (non-specific binding) or absence (total binding) of unlabelled
PK11195 (1 µM) in a final volume of 500 mL of assay buffer for 90 min at 0 ˝C. For the saturation
experiments, aliquots of human astrocyte membranes (20 µg of proteins) were incubated with eight
different concentrations of [3H]-PK11195 (0.5–30 nM) in duplicate using the conditions described
above. In each assay, the final ethanol concentration in the incubation buffer was less than 1% and did
not interfere with specific [3H]-PK11195 binding.
4.8. Statistical Analysis
The data are reported as the means˘ SEM of at least three independent experiments. All statistical
analyses were performed using GraphPad 5.0 Prism Software (GraphPad Software, La Jolla, CA, USA).
One-way ANOVA with Bonferroni’s post-test and Spearman’s correlation analyses were used to assess
the statistical significance of the data. A p value ď 0.05 was considered statistically significant.
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